Ahmed Negida, MBBCh, PhD

09/10/2025

Subthalamic Deep Brain Stimulation (STN-BD) significantly relieves gastrointestinal symptoms and improves gastric motility in patients with Parkinson's Disease, with sustained benefits over 12 months. Future studies should assess long-term effects and optimize stimulation parameters for autonomic dysfunction.

09/09/2025

Glymphatic dysfunction, measured by Diffusion Tensor Image Analysis ALong the Perivascular Space (DTI-ALPS index) is associated with early post-stroke cognitive impairment. In patients with subcortical infarct, MoCA scores at 7 days showed significant correlation with lesion-side DTI-ALPS index (r = 0.510, p = 0.005) but not with non-lesion DTI-ALPS values (r = 0.174, p = 0.259). Notably, significant correlations between MoCA scores at 90 days post-stroke and DTI-ALPS index were consistently demonstrated in the lesion, non-lesion, and mean bilateral measurements.

https://pmc.ncbi.nlm.nih.gov/articles/PMC12283319/

09/05/2025

Last week, I completed the IMPACT-AD 2025 fellowship track in San Diego, CA. A comprehensive training program in clinical trials for Alzheimer’s disease and related dementias provided by national leaders in the field through the Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD), funded by the National Institute on Aging - NIH and Alzheimer's Association

09/03/2025

Cholinesterase inhibitors (ChEIs) have demonstrated both tolerability and efficacy in treating dementia with Lewy bodies (DLB), yet they remain under-prescribed. This underutilization is influenced by factors such as race, ethnicity, and geographical region, which significantly impact the likelihood of receiving a ChEI prescription. Given the benefits of ChEIs for DLB patients, it is crucial to promote their use more widely across diverse patient populations.

https://pubmed.ncbi.nlm.nih.gov/40687401/

07/13/2025

Today, we started the 2025 mentorship program offered (for FREE) to 8751 medical students, trainees, and physicians in the MENA region. The first workshop was about Crafting a Powerful Professional CV for Medical Careers with a focus on rotations, research fellowships, and postgraduate degrees.

04/15/2025

Our research work has been featured in Neurology Today. I received a call two weeks ago inquiring about our ’s disease research work subtyping PD using tools. More here: https://journals.lww.com/neurotodayonline/blog/breakingnews/pages/post.aspx?PostID=1581 Special thanks to Dr. Barrett and the division chair Dr. Berman

04/15/2025

Thanks to Ibrahim Serag, Ahmed Y Azzam, Amr K Hassan, Rehab Adel Diab, Mohamed Diab, Mahmoud Tarek Hefnawy, and Mohamed Ahmed Ali for compiling this excellent and timely review.

Background Parkinson’s Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta. PD is diagnosed by a combination of motor symptoms including bradykinesia, resting tremors, rigidity and postural instability. Pr...

04/14/2025

“It is the mark of an educated mind to be able to entertain a thought without accepting it.” ― Aristotle, Metaphysics

04/09/2025

Today, I presented some preliminary data from our disease subtyping work at .. Do ’s disease patients with mild cognitive impairment and MRI evidence of cholinergic degeneration represent a distinct subtype?

Thanks to professors, colleagues, and friends who attended my presentation today 🫶🏻

04/05/2025

Attending the 2025